Equities Analysts Set Expectations for TSE:BHC Q2 Earnings

Bausch Health Companies Inc. (TSE:BHC) – Equities researchers at Zacks Research raised their Q2 2026 earnings per share (EPS) estimates for shares of Bausch Health Companies in a research report issued on Friday, July 24th. Zacks Research analyst Team now expects that the company will post earnings of $1.35 per share for the quarter, up from their prior forecast of $1.31. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $5.54 EPS and Q1 2027 earnings at $1.13 EPS.

Bausch Health Companies (TSE:BHC) last announced its quarterly earnings data on Wednesday, April 29th. The company reported C$1.08 earnings per share for the quarter. The firm had revenue of C$3.51 billion during the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.

Separately, Jefferies Financial Group raised shares of Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 22nd. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Bausch Health Companies presently has a consensus rating of “Hold”.

Bausch Health Companies Stock Down 0.5%

Shares of TSE BHC opened at C$6.25 on Monday. The firm has a fifty day simple moving average of C$7.02 and a two-hundred day simple moving average of C$7.66. The firm has a market capitalization of C$2.33 billion, a PE ratio of -1.93, a price-to-earnings-growth ratio of 0.21 and a beta of 0.97. The company has a current ratio of 1.32, a quick ratio of 0.58 and a debt-to-equity ratio of -1,009.96. Bausch Health Companies has a 12 month low of C$6.10 and a 12 month high of C$11.97.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.